JP2025508402A - 医薬製剤 - Google Patents
医薬製剤 Download PDFInfo
- Publication number
- JP2025508402A JP2025508402A JP2024548368A JP2024548368A JP2025508402A JP 2025508402 A JP2025508402 A JP 2025508402A JP 2024548368 A JP2024548368 A JP 2024548368A JP 2024548368 A JP2024548368 A JP 2024548368A JP 2025508402 A JP2025508402 A JP 2025508402A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- amount
- amino
- pharma
- ceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202211009181 | 2022-02-21 | ||
| IN202211009181 | 2022-02-21 | ||
| PCT/IB2023/051532 WO2023156979A1 (en) | 2022-02-21 | 2023-02-20 | Pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508402A true JP2025508402A (ja) | 2025-03-26 |
| JP2025508402A5 JP2025508402A5 (https=) | 2026-02-20 |
Family
ID=85476156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548368A Pending JP2025508402A (ja) | 2022-02-21 | 2023-02-20 | 医薬製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250161223A1 (https=) |
| EP (1) | EP4482471A1 (https=) |
| JP (1) | JP2025508402A (https=) |
| KR (1) | KR20240150600A (https=) |
| CN (1) | CN118715005A (https=) |
| AU (1) | AU2023221615A1 (https=) |
| CA (1) | CA3251234A1 (https=) |
| IL (1) | IL314206A (https=) |
| MX (1) | MX2024009967A (https=) |
| TW (1) | TW202342040A (https=) |
| WO (1) | WO2023156979A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4580606A1 (en) * | 2022-08-31 | 2025-07-09 | Astrazeneca AB | Pharmaceutical formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| MX2021009562A (es) | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1. |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| EP3923941B1 (en) | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and ribociclib |
| EP4110338A1 (en) | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
-
2023
- 2023-02-18 TW TW112105963A patent/TW202342040A/zh unknown
- 2023-02-20 US US18/839,600 patent/US20250161223A1/en active Pending
- 2023-02-20 KR KR1020247030717A patent/KR20240150600A/ko active Pending
- 2023-02-20 CN CN202380021982.XA patent/CN118715005A/zh active Pending
- 2023-02-20 JP JP2024548368A patent/JP2025508402A/ja active Pending
- 2023-02-20 WO PCT/IB2023/051532 patent/WO2023156979A1/en not_active Ceased
- 2023-02-20 AU AU2023221615A patent/AU2023221615A1/en active Pending
- 2023-02-20 IL IL314206A patent/IL314206A/en unknown
- 2023-02-20 CA CA3251234A patent/CA3251234A1/en active Pending
- 2023-02-20 MX MX2024009967A patent/MX2024009967A/es unknown
- 2023-02-20 EP EP23708903.2A patent/EP4482471A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL314206A (en) | 2024-09-01 |
| US20250161223A1 (en) | 2025-05-22 |
| CA3251234A1 (en) | 2023-08-24 |
| WO2023156979A1 (en) | 2023-08-24 |
| AU2023221615A1 (en) | 2024-07-25 |
| CN118715005A (zh) | 2024-09-27 |
| KR20240150600A (ko) | 2024-10-15 |
| EP4482471A1 (en) | 2025-01-01 |
| MX2024009967A (es) | 2024-08-26 |
| TW202342040A (zh) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7550393B2 (ja) | 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法 | |
| JP6503317B2 (ja) | Ｃ−ｍｅｔ調節剤の薬学的組成物 | |
| JP6577143B2 (ja) | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 | |
| US20140186407A9 (en) | C-Met Modulator Pharmaceutical Compositions | |
| JP2018177815A (ja) | エスシタロプラム医薬組成物 | |
| JP7665702B2 (ja) | アキシチニブを含有する医薬組成物 | |
| WO2020186812A1 (zh) | 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用 | |
| JP2025508402A (ja) | 医薬製剤 | |
| JP7356119B2 (ja) | 置換ブテンアミド医薬組成物及びその製造方法 | |
| JP7370126B2 (ja) | エルロチニブを有効成分とする医薬錠剤 | |
| KR101739731B1 (ko) | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 | |
| JP7370125B2 (ja) | エルロチニブを有効成分とする医薬錠剤 | |
| KR20240016319A (ko) | 프탈라지논 유도체를 이용한 장애 치료 방법 | |
| TWI912013B (zh) | 晶體、藥物組合物及其製備方法和應用 | |
| KR20180103090A (ko) | 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물의 제조 방법 | |
| JP2020147542A (ja) | ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する多層錠 | |
| WO2023238929A1 (ja) | ピミテスピブを含有する医薬組成物 | |
| WO2025252098A1 (zh) | Glp-1受体激动剂的口服药物组合物及其制备方法 | |
| KR20180103089A (ko) | 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물 | |
| WO2024251197A1 (zh) | Eed抑制剂固体分散体、包含其的口服制剂及其制备方法 | |
| JP2021165266A (ja) | ビルダグリプチン錠剤およびその製造方法 | |
| JP2019507151A (ja) | ピロロ縮合複素６員環化合物を含有する医薬組成物 | |
| WO2025140560A1 (zh) | 间变性淋巴瘤激酶抑制剂的药物组合物及其制备方法 | |
| WO2026041105A1 (zh) | 一种吡唑类衍生物抑制剂的药物组合物及制备方法 | |
| TW202612693A (zh) | Glp-1受體激動劑的口服藥物組合物及其製備方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260212 |